Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 11:43 p.m.

    📋 BLACK DIAMOND THERAPEUTICS, INC. (BDTX) - Financial Results

    Filing Date: 2022-08-09

    Accepted: 2022-08-09 07:26:59

    Event Type: Financial Results

    Event Details:

    Black Diamond Therapeutics (BDTX) Reports Q3 2022 Financial Results Black Diamond Therapeutics (BDTX) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 160890
      • 1535 is designed to be a potent, selective, irreversible and brain
      • penetrant MasterKey inhibitor of epidermal growth factor receptor (EGFR) mutations expressed in glioblastoma multiforme (GBM) and resistance mutations in non
      • small cell lung cancer (NSCLC), including de novo resistance and acquired resistance to third generation EGFR inhibitors.

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Operating Expenses Loss From Operations -34.72K -48.85K $14.14K +28.94%
    Interest Income 948.00 792.00 $156.00 +19.70%
    Total Other Income Expense 364.00 415.00 $-51.00 -12.29%
    Net Loss -34.35K -34.35K $0.00 +0.00%
    Net Loss Per Share -0.95 -0.95 $0.00 +0.00%
    Loss from Operations -34.72K -48.85K $14.14K +28.94%
    Interest Income 948.00 792.00 $156.00 +19.70%
    Total Other Income/(Expense) 364.00 415.00 $-51.00 -12.29%
    Net Loss -34.35K -34.35K $0.00 +0.00%

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Black Diamond Therapeutics
    • CIK: 0001701541
    • Ticker Symbol: BDTX
    • Period End Date: 2022-08-09
    • Document Type: 8-K

Search

News categories